• Bladder cancer
• Blood cancers
• Brain cancer
• Colorectal cancer
• Esophageal cancer
• Head and Neck cancer
• Immunotherapy¹
• Liver cancer
• Mesothelioma
• Metastatic cancers²
• Neuroblastoma
• Pediatric, adolescent, and young adult cancers³
• Pediatric brain tumors
• Stomach cancer

¹As derived from the NCI Dictionary of Cancer Terms (https://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=45729). Immunotherapy is a biological therapy that uses substances to stimulate or suppress the immune system to help the body fight cancer.

² For research funded under the FY20 PRCRP Topic Area metastatic cancers, research proposed must be targeted to cancer that has spread from its original location to another place in the body, representing what is known as stage III and stage IV cancer diagnoses. While recent research has revealed that there is a genetic basis for susceptibility or resistance to metastasis, more research is needed to develop a comprehensive understanding of this complex process. Applications to the metastatic cancer topic area should focus on the process of metastasis and not the cancer type (i.e., an agnostic interrogation of the process of metastasis). All research funded under the FY20 PRCRP must follow Congressional language (research applications in the areas of breast, kidney, lung (excluding mesothelioma), prostate, pancreatic, rare cancer, ovarian cancer or melanoma will not be accepted). The inclusion of the individual Department of Defense Rare Cancer Research Program shall not prohibit the PRCRP from funding the above mentioned cancers or cancer subtypes that may be rare by definition.

³The definition of adolescents and young adults is derived from the National Cancer Institute (NCI) (https://www.cancer.gov/types/aya). Research should be targeted toward children (ages 0-14 years), adolescents (ages 15-24 years), and/or young adults (ages 25-39 years).